About Us
For over 60 years delivering quality
Centroflora Group has spared no efforts in valuing Brazilian biodiversity as a source of Innovation for the Phytomedicines market.
With 64 years of history, Centroflora maintains its tradition as a manufacturer of botanical extracts, essential oils and isolated ingredients for the pharmaceutical industry. In recent years, it has also been consolidating itself as a national manufacturer of Active Pharmaceutical Ingredients (APIs), through new partnerships and investments to adapt its production and commercial structure.
Centroflora has technologies and processes that allow the isolation, extraction, concentration and drying of differentiated natural assets, with assured quality and traceability. As a result, it offers the market a wide variety of extracts from different regions of the planet, with special attention to those derived from Brazilian biodiversity, with total sustainability and respect for the environment; in other words, Centroflora has always acted in line with the principles that today are known as ESG.
Centroflora Group includes: (i) Anidro do Brasil; (ii) Phytobios, a company dedicated to radical and disruptive research and development, and (iii) Floravida Institute, a non-profit socio-environmental organization (NGO). In 2018, a joint venture called Brazbio has been created.
Mission
Vision
Values
1957
Foundation of Centroflora Group.
1991
Opening of the Drying Plant, in Botucatu-SP.
2001
Opening of the Botanic Extract Plant-SP.
2002
Creation of Floravida Institute, a non-profit organization managed by the Group.
2003
Acquisition of the Pharmochemical Plant in Paranaíba-PI and creation of the Partnerships for a Better World Program.
2005
Acquisition of the agricultural area in Paranaíba-PI
2008
Creation of the Jaborandi Valorization Program.
2011
Opening of the Oil Extraction Plant in Parnaíba-PI.
2012
Incorporation of 100% of the shares of Phytobios, until then a partner of Centroflora Group.
2014
Creation of Centroflora CMS, a Joint Venture between Centroflora and CMS.
2016
Incorporation of ASM Research Chemicals and L4P Foundation, specializing in pharmaceutical logistics.
2017
Sale of the nutraceutical sector to Givaudan.
2018
Completion of the CMS Joint Venture and creation of a distribution agreement between Centroflora and CMS (currently C²Pharma)
2018
Creation of Brazbio, a Joint Venture between Givaudan and Centroflora, with shared management and focused on the development of sociobiodiversity production chains, continuing the work developed within the “Partnerships for a Better World Program”.
2018
Centroflora IFA: delivery of a synthesis plant in Paranaíba-PI, with an investment of 18 million and a transfer project for the production of new APIs and prospecting for Cannabidiol production.
2019
Opening of Centroflora Inova in Campinas (SP)
2020
Opening of the Pilot Plant, of the new plant extract factory in Paranaíba (PI) and the beginning of the works of the new plant in Botucatu (SP).
2021
Start of activities at the new plant in Botucatu (Spray Dryer)
2021
Centroflora Agro
